MedKoo Cat#: 555397 | Name: SPHINX31
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SPHINX31 is a potent inhibitor of serine/arginine-rich protein kinase 1 (SRPK1; IC50 = 5.9 nM).

Chemical Structure

SPHINX31
CAS#1818389-84-2

Theoretical Analysis

MedKoo Cat#: 555397

Name: SPHINX31

CAS#: 1818389-84-2

Chemical Formula: C27H24F3N5O2

Exact Mass: 507.1882

Molecular Weight: 507.52

Elemental Analysis: C, 63.90; H, 4.77; F, 11.23; N, 13.80; O, 6.30

Price and Availability

Size Price Availability Quantity
5mg USD 125.00 Ready to ship
10mg USD 200.00 Ready to ship
25mg USD 450.00 Ready to ship
50mg USD 800.00 Ready to ship
100mg USD 1,450.00 Ready to ship
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
SPHINX31; SPHINX-31; SPHINX 31;
IUPAC/Chemical Name
5-(4-pyridinyl)-N-[2-[4-(2-pyridinylmethyl)-1-piperazinyl]-5-(trifluoromethyl)phenyl]-2-furancarboxamide
InChi Key
VURLRACCOCGFDB-UHFFFAOYSA-N
InChi Code
InChI=1S/C27H24F3N5O2/c28-27(29,30)20-4-5-23(35-15-13-34(14-16-35)18-21-3-1-2-10-32-21)22(17-20)33-26(36)25-7-6-24(37-25)19-8-11-31-12-9-19/h1-12,17H,13-16,18H2,(H,33,36)
SMILES Code
O=C(C1=CC=C(C2=CC=NC=C2)O1)NC3=CC(C(F)(F)F)=CC=C3N4CCN(CC5=NC=CC=C5)CC4
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO and ethanol
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
SPHINX31 is a potent and selective inhibitor of SRPK1 with an IC50 of 5.9 nM.
In vitro activity:
SPHINX31 may have therapeutic potential in the treatment of cholangiocarcinoma (CCA). SPHINX31 (0.3-10 μM) had no inhibitory effects on CCA cells' viability and proliferation. However, SPHINX31 decreased the mRNA expression of pro-angiogenic VEGF-A165a isoform. SPHINX31 attenuated SRSF1 phosphorylation and nuclear localization, and increased the ratio of VEGF-A165b/total VEGF-A proteins. Reference: Toxicol In Vitro. 2022 Aug;82:105385. https://pubmed.ncbi.nlm.nih.gov/35568131/
In vivo activity:
In a diabetic rat model, SRPK1 inhibition by SPHINX31, administered as an eye drop, protected the retinal barrier from hyperglycemia-associated loss of integrity. SRPK1 was activated by high glucose (HG), in a PKC-dependent manner, and was blocked by SPHINX31. Reference: Am J Physiol Heart Circ Physiol. https://pubmed.ncbi.nlm.nih.gov/35302878/
Solvent mg/mL mM comments
Solubility
DMSO 17.5 34.48
Ethanol 12.0 23.65
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 507.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Gu YY, Tan XH, Song WP, Song WD, Yuan YM, Xin ZC, Wang JD, Fang D, Guan RL. Icariside Ⅱ Attenuates Palmitic Acid-Induced Endothelial Dysfunction Through SRPK1-Akt-eNOS Signaling Pathway. Front Pharmacol. 2022 Jun 30;13:920601. doi: 10.3389/fphar.2022.920601. PMID: 35846993; PMCID: PMC9280058. 2. Supradit K, Boonsri B, Duangdara J, Thitiphatphuvanon T, Suriyonplengsaeng C, Kangsamaksin T, Janvilisri T, Tohtong R, Yacqub-Usman K, Grabowska AM, Bates DO, Wongprasert K. Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis. Toxicol In Vitro. 2022 Aug;82:105385. doi: 10.1016/j.tiv.2022.105385. Epub 2022 May 11. PMID: 35568131. 3. Malhi NK, Allen CL, Stewart E, Horton KL, Riu F, Batson J, Amoaku W, Morris JC, Arkill KP, Bates DO. Serine-arginine-rich protein kinase-1 inhibition for the treatment of diabetic retinopathy. Am J Physiol Heart Circ Physiol. 2022 Jun 1;322(6):H1014-H1027. doi: 10.1152/ajpheart.00001.2022. Epub 2022 Mar 18. PMID: 35302878; PMCID: PMC9109797. 4. Stevens M, Star E, Lee M, Innes E, Li L, Bowler E, Harper S, Bates DO, Oltean S. The VEGF-A exon 8 splicing-sensitive fluorescent reporter mouse is a novel tool to assess the effects of splicing regulatory compounds in vivo. RNA Biol. 2019 Dec;16(12):1672-1681. doi: 10.1080/15476286.2019.1652522. Epub 2019 Aug 21. PMID: 31432737; PMCID: PMC6844573.
In vitro protocol:
1. Gu YY, Tan XH, Song WP, Song WD, Yuan YM, Xin ZC, Wang JD, Fang D, Guan RL. Icariside Ⅱ Attenuates Palmitic Acid-Induced Endothelial Dysfunction Through SRPK1-Akt-eNOS Signaling Pathway. Front Pharmacol. 2022 Jun 30;13:920601. doi: 10.3389/fphar.2022.920601. PMID: 35846993; PMCID: PMC9280058. 2. Supradit K, Boonsri B, Duangdara J, Thitiphatphuvanon T, Suriyonplengsaeng C, Kangsamaksin T, Janvilisri T, Tohtong R, Yacqub-Usman K, Grabowska AM, Bates DO, Wongprasert K. Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis. Toxicol In Vitro. 2022 Aug;82:105385. doi: 10.1016/j.tiv.2022.105385. Epub 2022 May 11. PMID: 35568131.
In vivo protocol:
1. Malhi NK, Allen CL, Stewart E, Horton KL, Riu F, Batson J, Amoaku W, Morris JC, Arkill KP, Bates DO. Serine-arginine-rich protein kinase-1 inhibition for the treatment of diabetic retinopathy. Am J Physiol Heart Circ Physiol. 2022 Jun 1;322(6):H1014-H1027. doi: 10.1152/ajpheart.00001.2022. Epub 2022 Mar 18. PMID: 35302878; PMCID: PMC9109797. 2. Stevens M, Star E, Lee M, Innes E, Li L, Bowler E, Harper S, Bates DO, Oltean S. The VEGF-A exon 8 splicing-sensitive fluorescent reporter mouse is a novel tool to assess the effects of splicing regulatory compounds in vivo. RNA Biol. 2019 Dec;16(12):1672-1681. doi: 10.1080/15476286.2019.1652522. Epub 2019 Aug 21. PMID: 31432737; PMCID: PMC6844573.
1: Changphasuk P, Inpad C, Horpaopan S, Khunchai S, Phimsen S, Surangkul D, Janvilisri T, Silsirivanit A, Kaewkong W. SRPK Inhibitors Reduce the Phosphorylation and Translocation of SR Protein Splicing Factors, thereby Correcting BIN1, MCL-1 and BCL2 Splicing Errors and Enabling Apoptosis of Cholangiocarcinoma Cells. Front Biosci (Schol Ed). 2024 Sep 29;16(3):17. doi: 10.31083/j.fbs1603017. PMID: 39344395. 2: Li X, Nakashima K, Ito M, Matsuda M, Chida T, Sekihara K, Takahashi H, Kato T, Sawasaki T, Suzuki T. SRPKIN-1 as an inhibitor against hepatitis B virus blocking the viral particle formation and the early step of the viral infection. Antiviral Res. 2023 Dec;220:105756. doi: 10.1016/j.antiviral.2023.105756. Epub 2023 Nov 20. PMID: 37992764. 3: Wahid M, Pratoomthai B, Egbuniwe IU, Evans HR, Babaei-Jadidi R, Amartey JO, Erdelyi V, Yacqub-Usman K, Jackson AM, Morris JC, Patel PM, Bates DO. Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion. Cancer Immunol Immunother. 2023 Dec;72(12):4001-4014. doi: 10.1007/s00262-023-03534-z. Epub 2023 Nov 16. PMID: 37973660; PMCID: PMC10700477. 4: He C, Liu B, Wang HY, Wu L, Zhao G, Huang C, Liu Y, Shan B, Liu L. Inhibition of SRPK1, a key splicing regulator, exhibits antitumor and chemotherapeutic- sensitizing effects on extranodal NK/T-cell lymphoma cells. BMC Cancer. 2022 Oct 27;22(1):1100. doi: 10.1186/s12885-022-10158-6. PMID: 36303126; PMCID: PMC9609466. 5: Gu YY, Tan XH, Song WP, Song WD, Yuan YM, Xin ZC, Wang JD, Fang D, Guan RL. Icariside Ⅱ Attenuates Palmitic Acid-Induced Endothelial Dysfunction Through SRPK1-Akt-eNOS Signaling Pathway. Front Pharmacol. 2022 Jun 30;13:920601. doi: 10.3389/fphar.2022.920601. PMID: 35846993; PMCID: PMC9280058. 6: Supradit K, Boonsri B, Duangdara J, Thitiphatphuvanon T, Suriyonplengsaeng C, Kangsamaksin T, Janvilisri T, Tohtong R, Yacqub-Usman K, Grabowska AM, Bates DO, Wongprasert K. Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis. Toxicol In Vitro. 2022 Aug;82:105385. doi: 10.1016/j.tiv.2022.105385. Epub 2022 May 11. PMID: 35568131. 7: Pogacar Z, Groot K, Jochems F, Dos Santos Dias M, Mulero-Sánchez A, Morris B, Roosen M, Wardak L, De Conti G, Velds A, Lieftink C, Thijssen B, Beijersbergen RL, Bernards R, Leite de Oliveira R. Genetic and compound screens uncover factors modulating cancer cell response to indisulam. Life Sci Alliance. 2022 May 9;5(9):e202101348. doi: 10.26508/lsa.202101348. PMID: 35534224; PMCID: PMC9095732. 8: Malhi NK, Allen CL, Stewart E, Horton KL, Riu F, Batson J, Amoaku W, Morris JC, Arkill KP, Bates DO. Serine-arginine-rich protein kinase-1 inhibition for the treatment of diabetic retinopathy. Am J Physiol Heart Circ Physiol. 2022 Jun 1;322(6):H1014-H1027. doi: 10.1152/ajpheart.00001.2022. Epub 2022 Mar 18. PMID: 35302878; PMCID: PMC9109797.